The InBody 570 will be on display at booth #306-308
CERRITOS, CA (October 30, 2018) – InBody, a medical device manufacturer, will attend the 23rd Clinical Applications for Age Management Medicine from November 1 to November 3 at the JW Marriott Starr Pass Resort & Spa in Tucson, AZ. InBody will have two InBody 570 devices on display to showcase how science-based techniques in body composition analysis can be integrated into a practice at booth #306-308.
“The InBody devices provide deep insight to guide treatments, target specific areas of improvement and can even reverse or prevent functional impairment, sarcopenia and frailty,” said Meggan Brunette, InBody regional manager. “InBody devices are non-invasive and easy-to-use, making them the ideal tool to implement into prevention and treatment programs.”
In 45 seconds or less, the InBody 570 can provide professionals with:
– Skeletal Muscle Index: Identify risk of sarcopenia and decreased mobility.
– Skeletal Muscle Mass: Monitor sarcopenia, disease risk and operative outcomes.
– Muscle-Fat Analysis: Assess sarcopenic obesity and disease risk.
– ECW/TBW Analysis: Assess if changes in ECW/TBW are a result of decreased muscle mass and low intracellular water
Medically validated InBody devices are space-efficient and don’t rely on empirical equations to determine an individual’s body composition. Information regarding professional demos and other InBody products will also be available at the booth. All InBody body composition analyzers, including the InBody 570, are FDA 501 (k) approved. More information regarding body composition applications for aging and frailty can be found here.
